"I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.
Cambray SmithJeremiah StoutAlex A AdjeiJan BucknerMark WentworthJon TilburtZubin MasterPublished in: Journal of the National Cancer Institute (2022)
The study provides foundational empirical data underlying challenging ambiguities by experienced oncologists familiar with off-trial use of investigational therapeutics and reaffirms the role of physicians and regulatory bodies in mitigating the risks of investigational drugs. Our findings highlight the need for medical centers to inform oncologists about RTT and other preapproval pathways so that they are able to address questions from patients interested in nontrial investigational drugs.
Keyphrases
- phase ii
- end stage renal disease
- ejection fraction
- clinical trial
- primary care
- chronic kidney disease
- advanced cancer
- newly diagnosed
- healthcare
- peritoneal dialysis
- open label
- mental health
- transcription factor
- randomized controlled trial
- electronic health record
- palliative care
- phase iii
- patient reported outcomes
- machine learning
- big data
- risk assessment
- deep learning
- drug induced
- artificial intelligence
- double blind